Related Experiment Video
Updated: Jul 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effects of cilostazol on lipid and fatty acid metabolism
N Nakamura1, H Osawa, H Yamabe
1The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki-city, Aomori 036-8562, Japan. nnakamur-tym@umin.ac.jp
Abstract:
Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties. Randomised, double-blind, placebo-controlled trials in 2702 patients with intermittent claudication demonstrated that cilostazol significantly increased walking distances compared with placebo. Furthermore, the agent has beneficial effects on the serum lipid profile and fatty acid composition in plasma. Consequently, cilostazol may be useful to prevent atherosclerosis from progressing by ameliorating lipid and fatty acid metabolism.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Drugs for Treatment of Constipation-Predominant IBS
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Lipid Catabolism

